Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ICVX Stock Summary
Top 10 Correlated ETFs
ICVX
In the News

Wall Street Analysts Believe Icosavax, Inc. (ICVX) Could Rally 175.87%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 175.9% in Icosavax, Inc. (ICVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Icosavax, Inc. (ICVX) is on the Move, Here's Why the Trend Could be Sustainable
Icosavax, Inc. (ICVX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
SEATTLE, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in the Cantor Fitzgerald Global Healthcare Conference 2023, taking place from September 26-28, 2023 in New York City.

Icosavax (ICVX) Up on Positive VLP Vaccine Candidate Data
Icosavax (ICVX) surges on positive data from the clinical study of IVX-A12, targeting respiratory syncytial virus and human metapneumovirus in older adults.

Why Shares of Icosavax Jumped on Tuesday
Icosavax also initiated a $67.8 million stock sale. The biopharmaceutical company's pipeline also includes vaccines to treat influenza and severe acute respiratory syndrome coronavirus.

Should You Buy Icosavax (ICVX) Ahead of Earnings?
Icosavax (ICVX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Icosavax, Inc. (ICVX) Reports Q1 Loss, Lags Revenue Estimates
Icosavax, Inc. (ICVX) came out with a quarterly loss of $0.60 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.60 per share a year ago.

3 Biotech Stocks to Watch for Potential Breakthroughs
Biotech stock fortunes hinge upon potential, progress, and the ultimate realization of drugs and devices that treat diseases. Stringent regulatory processes and long development times result in substantial costs.

Icosavax (ICVX) Up 112% on Upbeat Data From RSV Jab Study
Data from an early-stage study showed that Icosavax's (ICVX) investigational RSV vaccine exhibited sustained immunologic response following six months of dose administration.

Icosavax, Inc. (ICVX) Reports Q3 Loss, Lags Revenue Estimates
Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of 3.51% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ICVX Financial details
ICVX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | |
Net income per share | -0.51 | -6.67 | -3.78 | -2.23 | |
Operating cash flow per share | -0.45 | -4.94 | -2.15 | -1.55 | |
Free cash flow per share | -0.45 | -4.94 | -2.2 | -1.83 | |
Cash per share | 2.25 | 4.56 | 15.53 | 5.5 | |
Book value per share | -0.8 | -9.28 | 15.49 | 5.49 | |
Tangible book value per share | -0.8 | -9.28 | 15.49 | 5.49 | |
Share holders equity per share | -0.8 | -9.28 | 15.49 | 5.49 | |
Interest debt per share | 0 | 1.83 | 0.01 | 0.14 | |
Market cap | 358.11M | 100.65M | 411.06M | 315.42M | |
Enterprise value | 335.03M | 92.48M | 131.98M | 265.37M | |
P/E ratio | -68.92 | -5.25 | -6.05 | -3.57 | |
Price to sales ratio | 0 | 0 | 0 | 0 | |
POCF ratio | -78.38 | -7.08 | -10.67 | -5.11 | |
PFCF ratio | -78.38 | -7.08 | -10.39 | -4.33 | |
P/B Ratio | -43.44 | -3.77 | 1.48 | 1.45 | |
PTB ratio | -43.44 | -3.77 | 1.48 | 1.45 | |
EV to sales | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -62.07 | -4.94 | -2.03 | -2.79 | |
EV to operating cash flow | -73.33 | -6.51 | -3.42 | -4.3 | |
EV to free cash flow | -73.33 | -6.5 | -3.34 | -3.65 | |
Earnings yield | -0.01 | -0.19 | -0.17 | -0.28 | |
Free cash flow yield | -0.01 | -0.14 | -0.1 | -0.23 | |
Debt to equity | 0 | -0.19 | 0 | 0.04 | |
Debt to assets | 0 | 0.31 | 0 | 0.04 | |
Net debt to EBITDA | 4.28 | 0.44 | 4.3 | 0.53 | |
Current ratio | 19.04 | 2.77 | 31.02 | 16.24 | |
Interest coverage | 0 | -56.53 | -436.17 | 28.81 | |
Income quality | 0.86 | 0.75 | 0.58 | 0.67 | |
Dividend Yield | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.03 | 0.18 | |
Capex to revenue | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -11 | -12.27 | -12.92 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | |
Graham number | 3.03 | 37.3 | 36.32 | 16.59 | |
ROIC | 0.64 | 0.88 | -0.24 | -0.39 | |
Return on tangible assets | -0.22 | -1.19 | -0.24 | -0.37 | |
Graham Net | -0.83 | -10.34 | 15.01 | 4.98 | |
Working capital | 22.07M | 10.33M | 277.32M | 210.13M | |
Tangible asset value | -8.24M | -26.7M | 278.22M | 218.16M | |
Net current asset value | -8.24M | -26.71M | 277.14M | 203.4M | |
Invested capital | 0 | -0.19 | 0 | 0.04 | |
Average receivables | 0 | 0 | 0 | 0 | |
Average payables | 0 | 1.36M | 2.91M | 3.4M | |
Average inventory | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | |
ROE | 0.63 | 0.72 | -0.24 | -0.41 | |
Capex per share | 0 | 0 | -0.06 | -0.28 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.52 | -0.54 | -0.55 | -0.59 | -0.44 | |
Operating cash flow per share | -0.44 | -0.23 | -0.52 | -0.43 | -0.38 | |
Free cash flow per share | -0.54 | -0.29 | -0.56 | -0.44 | -0.38 | |
Cash per share | 5.57 | 5.48 | 4.76 | 5.52 | 4.58 | |
Book value per share | 5.68 | 5.48 | 4.85 | 5.53 | 4.64 | |
Tangible book value per share | 5.68 | 5.48 | 4.85 | 5.53 | 4.64 | |
Share holders equity per share | 5.68 | 5.48 | 4.85 | 5.53 | 4.64 | |
Interest debt per share | 0.2 | 0.17 | 0.2 | 0.19 | 0.16 | |
Market cap | 125.61M | 316.1M | 239.33M | 444.57M | 387.74M | |
Enterprise value | 67.78M | 266.05M | 198.79M | 297.94M | 332.57M | |
P/E ratio | -1.51 | -3.68 | -2.65 | -4.19 | -4.4 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -7.23 | -35.11 | -11.06 | -23.13 | -20.44 | |
PFCF ratio | -5.89 | -27.36 | -10.31 | -22.34 | -20.4 | |
P/B Ratio | 0.56 | 1.45 | 1.2 | 1.79 | 1.67 | |
PTB ratio | 0.56 | 1.45 | 1.2 | 1.79 | 1.67 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -2.95 | -10.59 | -7.5 | -10.29 | -13.16 | |
EV to operating cash flow | -3.9 | -29.55 | -9.18 | -15.5 | -17.53 | |
EV to free cash flow | -3.18 | -23.03 | -8.56 | -14.97 | -17.5 | |
Earnings yield | -0.17 | -0.07 | -0.09 | -0.06 | -0.06 | |
Free cash flow yield | -0.17 | -0.04 | -0.1 | -0.04 | -0.05 | |
Debt to equity | 0.03 | 0.04 | 0.04 | 0.03 | 0.03 | |
Debt to assets | 0.03 | 0.04 | 0.04 | 0.03 | 0.03 | |
Net debt to EBITDA | 2.51 | 1.99 | 1.53 | 5.06 | 2.18 | |
Current ratio | 17.55 | 16.24 | 15.67 | 16.76 | 18.06 | |
Interest coverage | -19.83 | 11.78 | 41.25 | 0 | 0 | |
Income quality | 0.79 | 0.38 | 0.88 | 0.73 | 0.86 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.23 | 0.28 | 0.07 | 0.04 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -27.66 | -4.12 | -2.45 | -1.02 | -0.04 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 8.18 | 8.16 | 7.73 | 8.58 | 6.79 | |
ROIC | -0.09 | -0.1 | -0.11 | -0.11 | -0.1 | |
Return on tangible assets | -0.09 | -0.09 | -0.11 | -0.1 | -0.09 | |
Graham Net | 5.11 | 4.97 | 4.56 | 5.04 | 4.2 | |
Working capital | 215.7M | 210.13M | 189.27M | 236.69M | 222.28M | |
Tangible asset value | 225.66M | 218.16M | 200.08M | 247.72M | 232.38M | |
Net current asset value | 210.52M | 203.4M | 193.58M | 230.4M | 216.39M | |
Invested capital | 0.03 | 0.04 | 0.04 | 0.03 | 0.03 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 4.1M | 3.81M | 2.25M | 1.58M | 1.39M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.09 | -0.1 | -0.11 | -0.11 | -0.09 | |
Capex per share | -0.1 | -0.06 | -0.04 | -0.02 | 0 |
ICVX Frequently Asked Questions
What is Icosavax, Inc. stock symbol ?
Icosavax, Inc. is a US stock , located in Seattle of Wa and trading under the symbol ICVX
Is Icosavax, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $27. The lowest prediction is $27 and the highest is $27
What is ICVX stock prediction ?
What is Icosavax, Inc. stock quote today ?
Icosavax, Inc. stock price is $10.51 today.
Is Icosavax, Inc. stock public?
Yes, Icosavax, Inc. is a publicly traded company.